GlassScriptPhysician profile
Simon Sunghwan Oh
NPI 1780427773
$2,918.56
in general payments reported to CMS, 2019-2025
25 companies · $2,242 in 2025
The $2,242 reported for 2025 was more than what 94% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $57.61 · 2024: $619 · 2025: $2,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,918.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $795.88 | 2024-2025 | |
| Pfizer INC. | $333.75 | 2024-2025 | |
| Lundbeck LLC | $316.33 | 2024-2025 | Vyepti, Rexulti |
| Eisai INC. | $189.67 | 2024-2025 | |
| Genentech USA, INC. | $158.75 | 2025 | Ocrevus, Ocrevus Zunovo |
| Tg Therapeutics, INC. | $156.96 | 2025 | |
| Vanda Pharmaceuticals INC. | $115.93 | 2024-2025 | Ponvory |
| Biogen, INC. | $95.62 | 2023-2025 | Aduhelm, Vumerity, Tysabri |
| Lilly USA, LLC | $89.80 | 2024-2025 | Kisunla, Amyvid |
| Novartis Pharmaceuticals Corporation | $86.08 | 2024-2025 | |
| Amgen INC. | $77.80 | 2024-2025 | Uplizna |
| Ucb, INC. | $77.25 | 2025 | Briviact, Rystiggo |
| Alexion Pharmaceuticals, INC. | $53.69 | 2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $51.48 | 2024-2025 | Austedo Xr, Austedo Xr |
| C2n Diagnostics, LLC | $51.43 | 2025 | Precivityad2 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $43.17 | 2025 | Symbravo |
| Neurelis, INC. | $40.60 | 2025 | Valtoco |
| Catalyst Pharmaceuticals, INC. | $29.37 | 2025 | |
| Merz Pharmaceuticals, LLC | $25.87 | 2025 | Xeomin, Inbrija |
| Sk Life Science, INC. | $24.78 | 2025 | |
| Boston Scientific Corporation | $24.68 | 2025 | General - Dbs |
| Xeris Pharmaceuticals, INC. | $23.66 | 2024 | Keveyis |
| Amneal Pharmaceuticals LLC | $21.21 | 2025 | Crexont |
| Novo Nordisk INC | $19.59 | 2024 | Ozempic |
| Aucta Pharmaceuticals, INC. | $15.21 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Oh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.